Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Osiris Therapeutics (OSIR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 162,636
  • Shares Outstanding, K 34,530
  • Annual Sales, $ 59,870 K
  • Annual Income, $ -1,790 K
  • 36-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.09
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/30/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.1000 +14.88%
on 03/28/17
5.1500 -8.54%
on 04/03/17
+0.7600 (+19.24%)
since 03/27/17
3-Month
2.6700 +76.40%
on 03/15/17
6.1800 -23.79%
on 03/06/17
-1.1900 (-20.17%)
since 01/27/17
52-Week
2.6700 +76.40%
on 03/15/17
7.3900 -36.27%
on 11/11/16
-1.2200 (-20.57%)
since 04/27/16

Most Recent Stories

More News
Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology

Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced...

OSIR : 4.7100 (-2.89%)
Osiris Therapeutics Announces Change in its Board of Directors

Osiris Therapeutics, Inc. (Pink Sheets:OSIR), announced today the passing of one of its Board Members, Yves Huwyler.

OSIR : 4.7100 (-2.89%)
Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage...

OSIR : 4.7100 (-2.89%)
OMER : 16.47 (+1.10%)
Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors

Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 7, 2017, confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp as...

OSIR : 4.7100 (-2.89%)
Osiris Provides Update Regarding NASDAQ Listing Matters

Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company") today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ").

OSIR : 4.7100 (-2.89%)
Peer-reviewed Publication on the use of Grafix(R) in High-Risk Peripheral Arterial Disease Patients with Treatment Refractory Ulcerations Demonstrating Durable Wound Closure

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that a new peer-reviewed manuscript by physician and surgeon Jonathan Smedley, DPM, FACFAS, entitled "Wound Closure in Smoking Peripheral Arterial...

OSIR : 4.7100 (-2.89%)
Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 2016 Revenue

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics, and sports medicine, today announced its preliminary...

OSIR : 4.7100 (-2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Support & Resistance

2nd Resistance Point 4.8633
1st Resistance Point 4.7867
Last Price 4.7100
1st Support Level 4.6667
2nd Support Level 4.6233

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.